Introduction
Osteoporosis is a serious but undervalued disease that affects .200 million people globally. 1 Defined as a deterioration of bone mass and microarchitecture, it can be classified into primary and secondary osteoporosis. The former is age related or idiopathic. Although it occurs in both sexes, postmenopausal women are more commonly affected.
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Secondary osteoporosis occurs as a result of medical conditions or medications affecting bone metabolism. 2 Hormonal agents, such as gonadotropin-releasing hormone (GnRH) agonists, inhibit gonadotropins' secretion leading to a hypogonadal state that resembles menopause in women and chemical castration in men. 3 Bone turnover, indicated by circulating osteoblast and osteoclast biochemical markers, increases progressively with the use of GnRH agonists. 4 This results in a 5-10 times higher rate of bone loss and a 6.5%-17% lower bone mass in patients managed with GnRH agonists compared to those without. 5, 6 The risk of fracture at any sites in men receiving GnRH agonist was 7.91/100 (relative risk 1.21, 95% CI 1.09-1.34) versus 6.55/100 among nonusers, with a significantly higher rate at the hip (relative risk 1.76, 95% CI 1.33-2.33). 7 Thus, the adverse skeletal effects of GnRH agonists should be taken seriously.
Osteoporotic fractures in men result are associated with short-and long-term morbidities characterized by pain, limitation of function, decreased health-related quality of life, and higher mortality rates. 8, 9 It is also a significant financial burden to the patients, the health care system, and the countries due to the medical expenses involved and the loss of productivity. 10 Although the existing pharmacological treatments for osteoporosis, such as bisphosphonates, denosumab, and teriparatide, are proven effective in increasing bone mineral density and reducing fractures, they come with some adverse side effects and are plagued by the problem of low compliance. 11, 12 The current preventive agents for osteoporosis are limited to calcium with or without vitamin D. The search for a more effective alternative agent is intensified with increasing demands from the patients.
Tocotrienols are a subset of the lipid-soluble vitamin E family derived from plant oil, apart from the more well-known tocopherols. 13, 14 Studies have shown that tocotrienol exerted bone protective effects in various animal models of osteoporosis, induced by primary female 15, 16 and male hypogonadism, 17 free radical, 18 nicotine, 19 and dexamethasone. 20 In one study of note, oral annatto tocotrienol supplementation for 8 weeks at 60 mg/kg in orchidectomized rats prevented deterioration of bone microstructures and calcium content. 17, 21 However, the skeletal effects of tocotrienol on osteoporosis induced by GnRH agonist have not been explored. Tocotrienol derived from annatto (Bixa orellana) bean contains ~90% delta-tocotrienol, 10% gamma-tocotrienol, and no alphatocopherol. 22 In comparison, vitamin E mixtures from palm 23 and rice bran contain high amount of alpha-tocopherol. 24 The unique composition of annatto tocotrienol provides an opportunity to study the bone protective effects of tocotrienol without the interference of alpha-tocopherol. Previous studies showed that the biological activities of tocotrienol were reduced with the addition of alpha-tocopherol. Of note, alphatocopherol attenuated the cholesterol-lowering effects and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibiting activities of tocotrienol. 25, 26 Since alpha-tocopherol competes with tocotrienols in binding with alpha-tocopherol transfer protein, a key transporter in determining the circulating vitamin E level in the body, the reduced biological activities of tocotrienol might be contributed by its decreased bioavailability in the presence of alpha-tocopherol. 27 An in vitro study also showed that alpha-tocopherol promoted osteoclast fusion and increased bone resorption. This effect was not shared by tocotrienols. 28 The objective of the current study was to evaluate the effects of annatto tocotrienol at 60 and 100 mg/kg body weight on bone microstructural indices, bone calcium content, and bone biomechanical parameters in male osteoporosis model induced by buserelin, a GnRH agonist. We hypothesized that annatto tocotrienol could prevent bone deterioration in hypogonadal male rats, and the effects would be dose dependent. We hope the findings from this study will validate the use of annatto tocotrienol as a preventive agent against male osteoporosis due to GnRH agonist.
Methods
Preparation of treatment
Natural tocotrienol from annatto (B. orellana) bean (DeltaGold ® 70; lot number: 4II5-AAM4-70), containing 86.3% delta-tocotrienol and 13.9% gamma-tocotrienol, was a gift from American River Nutrition Inc. (Hadley, MA, USA). It was diluted with vitamin E-free corn oil (MP Biomedicals, Illkirch, France) in a ratio of 1:10 before given to the rats. The use of vitamin E-free corn oil prevented the interaction of alpha-tocopherol on the absorption of tocotrienol.
animals and treatment
Forty-six male Sprague Dawley rats aged 3 months were obtained from the Laboratory Animal Resource Unit of Universiti Kebangsaan Malaysia (Kuala Lumpur, Malaysia). The rats were housed individually in plastic cages at the animal laboratory of the Department of Pharmacology, University Kebangsaan Malaysia (Kuala Lumpur, Malaysia) under standard conditions (27°C, natural dark-light cycle, tap water, and standard rat chow ad libitum). After a week of acclimatization, the rats were randomized into six groups. The baseline control group (n=6) was sacrificed at the onset of the study. The normal control group (n=8) received X-ray microcomputed tomography (µcT) X-ray µCT scanning of the harvested tibia was performed using the Skyscan 1076 Scanner (Skyscan, Kartuizersweg Kontich, Belgium). The energy selected for this study was set at 70 kVp and 100 µA with high image resolution to obtain the best contrast between bone and soft tissues. The volume of interest (200 slices) selected for trabecular bone parameter was at the proximal metaphysis of the left tibia located 1.5 mm below the lowest point of the epiphyseal growth plate extending distally. For the cortical bone parameters, 100 slices were analyzed at the diaphysis region located 2.5 mm distal to the proximal metaphysis of the same tibia ( Figure 1 ).
Bone calcium content
The left femur cleaned of soft tissues was dried in an oven at 100°C for 24 hours. Next, it was ashed at 800°C for 12 hours. The end product was weighed and dissolved in 3 mL of nitric acid (Fisher Scientific, Shah Alam Selangor, Malaysia). Then, it was diluted in lanthanum chloride (Sigma-Aldrich Co., St Louis, MO, USA). The calcium content of the solution was determined by an atomic absorption spectrophotometer (AA-689; Shimadzu, Kyoto, Japan) at the wavelength of 422.7 nm.
Biomechanical strength
A precision universal tester (Autograph AG-10kNG; Shimadzu) with Trapezium X materials testing operation software was used to evaluate the biochemical strength of left femur. A three-point bending test was conducted on the femur cleaned of soft tissues. It was placed on an aluminum base, with the dorsal proximal femur placed on the onerounded edge-free notch while the distal diaphysis at the synostosis on the other side. The femur was moistened with PBS throughout the test. The roller stamp with the tip consisting of axle-led aluminum was driven down at the central femoral diaphysis (speed 5 mm/min; span length 10 mm) until the primary strength of 1 N was achieved ( Figure 2 ). The study ended automatically once a loss of force .20 N or a linear change of 2 mm was detected upon fracturing of the femur midshaft to avoid bursting of the specimens. The Trapezium X software was then used to analyze load (N), displacement (mm), stress (N/mm 2 ), strain (%), and elasticity (N/mm 2 ).
statistical analysis
Shapiro-Wilk test was used to assess the normality of the data. The change in µCT parameters, calcium content, and bone biomechanical strength parameters was compared using one-way analysis of variance with post 
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Results
Buserelin caused a significant reduction in bone volume, connective density as well as a significant increase in trabecular separation at the proximal tibia compared with the normal control (P,0.05). Annatto tocotrienol at both doses and calcium supplementation prevented these degenerative changes in the rats treated with buserelin (P,0.05). Trabecular thickness and structural model index were similar across all the study groups (P.0.05) (Figure 3 ). The cortical structural parameters including total area, cortical area, and percentage of cortical over total area were not significantly different among all the study groups (P.0.05). However, cortical thickness was significantly increased in the rats treated with annatto tocotrienol at 60 and 100 mg/kg compared with the buserelin group (P,0.05) (Figure 4) . Figure 5 shows the three-dimensional reconstruction of trabecular and cortical bones at the tibia of male rats after 3 months of treatment. Deterioration of trabecular bone was apparent for the BuC group. Trabecular bone was denser in the annatto tocotrienol-treated group (60 and 100 mg/kg) compared with the buserelin-treated groups. Cortical bone appeared to be thicker in the annatto tocotrienol-treated group compared with the BuC group.
Bone calcium level was significantly lower in the BuC compared with the normal control group (P.0.05). Both calcium and annatto tocotrienol (60 and 100 mg/kg) prevented the decrease in bone calcium level in the buserelin-treated rats (P,0.05) ( Figure 6 ).
Buserelin decreased biomechanical strength of the bone, indicated by a significant reduction in maximum load, strain, and elasticity of the buserelin-treated group compared with the normal control (P,0.05). Treatment with calcium and buserelin (60 and 100 mg/kg) prevented the decrease in load and elasticity (P,0.05). Furthermore, annatto tocotrienol at 60 and 100 mg/kg also increased the femoral stress value. Only annatto tocotrienol at 60 mg/kg prevented the reduction in strain parameter (P,0.05). There were no significant changes in displacement and stiffness among all the study groups (P.0.05) (Figure 7 ).
Discussion
The use of GnRH agonists, such as buserelin, is associated with a higher degree of bone loss in men. 29, 30 Our study showed that annatto tocotrienol can prevent the degenerative changes of the bone in rats receiving buserelin. Three closely associated aspects of bone health, ie, bone microstructure, calcium content, and biomechanical strength, were showcased in this study. As biomechanical strength is determined by both geometry and material properties of the bone, any changes in microstructure and calcium content would be reflected by the bone strength. 31 Annatto tocotrienol improved all three aspects of bone health, and its effects were comparable with calcium supplementation in this study.
The normal control group did not show any significant changes in all bone parameters compared with the baseline group. This is in agreement with previous studies showing that the bone did not experience significant modeling or deterioration within this life stage of male rats. 32 The lack of changes between baseline and control also showed that 
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skeletal effect of annatto tocotrienol in male rats any bone alternations observed during the experiment were caused by the treatment rather than the age of the rats. Buserelin induced significant deterioration of trabecular bone structure and bone calcium content after 3 months in this study. Tobias et al 33 reported that buserelin treatment for 90 days induced a significant decrease in bone volume, trabecular number, and thickness in female rats for 90 days. This occurred due to high bone turnover and calcium mobilization in rats receiving buserelin, evidenced by elevated urinary calcium and hydroxyproline. This ultimately resulted in a lower femur and total body calcium in female rats after 2 weeks of buserelin treatment. 34 We speculate that similar high bone turnover happened in the male rats receiving buserelin in this study, but markers of bone remodeling and calcium homeostasis were not tested. Hence, the exact mechanism of calcium loss from the femoral bone could not be confirmed. However, it is evident that the loss of microarchitecture (geometry properties) and calcium content (material properties) of the bone resulted in the decline of bone biomechanical strength in the buserelin-treated group.
The negative effects of buserelin on trabecular bone structure, bone calcium content, and femoral biomechanical Figure 3 Trabecular bone indices in the proximal tibia of the rats evaluated using µcT. Notes: The bar charts show the trabecular bone indices in the proximal tibia of the rats evaluated using µcT, ie, bone volume/total volume (A), trabecular number (B), trabecular thickness (C), trabecular separation (D), structural model index (E), and connectivity density (F). The data are shown as mean ± standard error of the mean. Same letters (a-e) indicate a significant difference between groups in each parameter. The statistical significant value set as P,0.05. Buc, buserelin control group; cac, calcium control group; anTT60, annatto-tocotrienol 60 mg/kg group; anTT100, annatto-tocotrienol 100 mg/kg group. Abbreviations: Bsl, baseline; nc, normal control; µcT, microcomputed tomography; sMi, structural model index; BV/TV, bone volume; Tb.Th, trabecular thickness; Tb.sp, trabecular separation; Tb.n, trabecular number; conn.D, connectivity density.
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Mohamad et al strength were reversed by annatto tocotrienol treatment. The skeletal protective effects of annatto tocotrienol were comparable to calcium supplementation. Chin et al 17 demonstrated that annatto tocotrienol at 60 mg/kg prevented bone loss in orchidectomized rats by increasing the expression of bone formation genes, such as collagen type I alpha 1, alkaline phosphatase, and beta-catenin, as well as decreasing the expression of receptor activator of nuclear factor Figure 4 cortical bone indices in the proximal tibia of the rats evaluated using µcT. Notes: The bar charts show the cortical bone indices in the proximal tibia of the rats evaluated using µcT, ie, total area (A), cortical area (B), cortical thickness (C), and cortical area/total area (D). The data are shown as mean ± standard error of the mean. Same letters (a and b) indicate a significant difference between groups in each parameter. The statistical significant value set as P,0.05. Buc, buserelin control group; cac, calcium control group; anTT60, annatto-tocotrienol 60 mg/kg group; anTT100, annatto-tocotrienol 100 mg/kg group. Abbreviations: Bsl, baseline; nc, normal control; µcT, microcomputed tomography; Tt.ar, total area; ct.ar, cortical area; ct.Th, cortical thickness; ct.ar/Tt.ar, cortical area over total area.
Figure 5
Three-dimensional µcT images of the trabecular and cortical microstructure of distal tibia metaphysis. Notes: Buc, buserelin control group; cac, calcium control group; anTT60, annatto-tocotrienol 60 mg/kg group; anTT100, annatto-tocotrienol 100 mg/kg group. Abbreviations: Bsl, baseline; nc, normal control; µcT, microcomputed tomography.
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Calcium in the form of hydroxyapatite is the principal inorganic component of bone. 36 A balance calcium homeostasis is important to ensure the integrity of the skeleton. 37 Excess mobilization of calcium from the bone reserve to the circulation will cause osteoporosis. The calcium conserving effects of tocotrienol have been demonstrated by previous studies. Norazlina et al 38 indicated that alpha-tocopherol was essential for normal calcium metabolism. An alpha-tocopheroldeficient diet could induce bone loss in animals. 38 Despite not being an essential nutrient in the body, supplementation of tocotrienol could protect skeletal calcium loss in various models of osteoporosis. Chin et al 21 showed that treatment of annatto tocotrienol (60 mg/kg) preserved the calcium level in orchidectomized rats after 2 months of treatment. Gammatocotrienol (60 mg/kg) for 8 weeks prevented calcium loss at the fourth lumbar vertebra of the rats treated by dexamethasone. 20 Our studies reaffirmed the previous findings and further showed that the effect of annatto tocotrienol on bone calcium content was comparable to calcium supplementation. However, we did not conduct calcium isotopic test to determine the increase in bone calcium content, which could be due to increased absorption, decreased excretion, or both.
Biomechanical test is the gold standard used for the assessment of bone strength. 39 Few studies have examined Figure 6 Posttreatment bone calcium level in rats.
Notes:
The bar charts show the posttreatment bone calcium level in rats. The data are shown as mean ± standard error of the mean. same letters (a-e) indicate a significant difference between groups in each parameter. The statistical significant value set as P,0.05. Buc, buserelin control group; cac, calcium control group; anTT60, annatto-tocotrienol 60 mg/kg group; anTT100, annatto-tocotrienol 100 mg/kg group. Abbreviations: Bsl, baseline; nc, normal control.
Figure 7 (Continued)
kappa-B ligand, a stimulator of osteoclast formation. AbdulMajeed et al 35 also showed that concurrent administration of delta-tocotrienol (60 mg/kg) and lovastatin (11 mg/kg) significantly increased bone formation and reduced bone resorption in ovariectomized rats after 8 weeks. This was achieved by upregulating the gene expression of bone morphogenetic protein-2. The previous studies did not examine the effects of tocotrienol on cortical bone. Our study showed that although cortical bone did not decline significantly in rats, annatto tocotrienol at both doses increased cortical Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
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Mohamad et al effects of tocotrienol on bone strength. In this study, the bone of the rats treated with annatto tocotrienol 60 and 100 mg/kg showed significant improvement in both extrinsic (load) and intrinsic biomechanical parameters (stress, strain, and elasticity). Load, reflected by the maximum amount of force needed to break the bone, represents the whole bone strength. 40 Femoral bones of the rats receiving annatto tocotrienol at both doses and calcium supplementation had greater strength because they withstood greater load than the untreated group. Stress is the strength of the bone tissue under a given loading condition. 41 Femoral bones of the annatto tocotrienol at both doses and calcium groups had a higher stress value compared with the untreated group. This indicated that the femurs of the treated groups absorbed a higher load before fracturing. Only annatto tocotrienol at dose 60 mg/kg significantly enhanced the strain of the femoral bone, indicating a better ability of the bone to withstand deformation. Elasticity is the ability of the bone to return its shape after removing the load. 42 Similar to previous indices, rats treated with annatto tocotrienol at both doses and calcium supplementation had a higher elasticity compared with the untreated group. Hence, the overall bone strength in the rats receiving annatto tocotrienol was greater than the untreated group and comparable to the calcium control. Shuid et al 43 showed that treatment of gamma-tocotrienol at 60 mg/kg significantly improved biomechanical strength of the femur in normal rats. The enhanced bone calcium content and bone microstructure caused by annatto tocotrienol had translated to a better bone biomechanical strength in the rats treated with annatto tocotrienol in this study.
Several limitations should be considered when interpreting the results of the present study. Only oral administration of annatto tocotrienol was tested in this study. A previous study established that the bioavailability of tocotrienol varied significantly according to the routes of administration, whereby the oral route was shown to have higher bioavailability compared to intramuscular and intraperitoneal injections. 44 Subcutaneous injection was shown to deposit reasonable amount of tocotrienol in the bone, 45 but it does not resemble the method of intake in humans. Biomechanical strength and bone calcium content were tested at the femur, but microstructural indices were obtained from the tibia. Due to the variation of trabecular and cortical bone at different sites, they might not correlate well with each other. Tibia, which is richer in trabecular bone, was expected to show a more rapid response to androgen deprivation and treatments than the femur. Annatto tocotrienol did not show dose-dependent effects on the bone in this study, whereby the skeletal improvement of the rats receiving 60 mg/kg annatto tocotrienol was similar to those receiving 100 mg/kg. We postulated that the maximal therapeutic potential of annatto tocotrienol on bone has been reached at 60 mg/kg. However, this speculation awaits evidence from extensive pharmacokinetic-pharmacodynamic studies. This is the first study to demonstrate the effects of annatto tocotrienol in a male osteoporotic model induced by buserelin. The skeletal effects of tocotrienol were comparable to calcium, indicating that it might provide a potential alternative for the prevention of osteoporosis. Since the rats were not deficient in dietary calcium at the first place, annatto tocotrienol might work for osteoporotic men with adequate calcium intake. The effects of tocotrienol in combination with calcium supplement in calcium deficiency model would be explored in further studies. 
Conclusion
Annatto tocotrienol at 60 mg/kg can prevent deterioration of trabecular bone induced with buserelin by preserving the microstructural integrity, calcium content, and biomechanical strength of the bone. Further increasing the dose of annatto tocotrienol does not provide added skeletal improvement. Tocotrienol may be useful to prevent bone loss in male patients using GnRH agonists.
